Home > Publications Database > Beyond the cerebello-thalamo-cortical tract: Remote structural changes after VIM-MRgFUS in essential tremor. > print

001     276825
005     20250318091451.0
024 7 _ |a 10.1016/j.parkreldis.2025.107318
|2 doi
024 7 _ |a pmid:39913957
|2 pmid
024 7 _ |a 1353-8020
|2 ISSN
024 7 _ |a 1873-5126
|2 ISSN
037 _ _ |a DZNE-2025-00338
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Krauss, Jonas
|b 0
245 _ _ |a Beyond the cerebello-thalamo-cortical tract: Remote structural changes after VIM-MRgFUS in essential tremor.
260 _ _ |a Amsterdam [u.a.]
|c 2025
|b Elsevier Science
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1740395528_19529
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Essential tremor (ET) is a progressive disorder characterized by altered network connectivity between the cerebellum, thalamus, and cortical regions. Magnetic Resonance-guided Focused Ultrasound (MRgFUS) of the ventral intermediate nucleus (VIM) is an effective, minimally invasive treatment for ET. The impact of MRgFUS interventions on regional Gray Matter Volume (GMV) are as yet not well understood.Forty-six patients with medication-resistant ET underwent unilateral VIM-MRgFUS. Voxel-based morphometry was applied to investigate GMV changes over a time span of 6 months in the whole brain and the thalamus in particular to investigate local and distant effects.Clinically, contralateral tremor significantly decreased by 68 % at 6 months following MRgFUS. In addition to local GMV decreases in thalamic nuclei (VIM, ventral lateral posterior, centromedian thalamus and pulvinar), VBM revealed remote GMV decreases in the ipsilesional insula and the anterior cingulate cortex as well as the contralesional middle occipital gyrus. Increased GMV was found in the right superior and middle temporal gyrus, as well as in the left inferior temporal gyrus. There was no significant correlation between regional GMV declines and tremor improvement. However, temporal volume increases were associated with improved motor-related functional abilities and quality of life outcomes.Our findings implicate distributed structural changes following unilateral VIM-MRgFUS. Structural losses could reflect Wallerian degeneration of VIM output neurons or plasticity due to decreased sensory input following tremor improvement.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Essential tremor
|2 Other
650 _ 7 |a MRgFUS
|2 Other
650 _ 7 |a Structural changes
|2 Other
650 _ 7 |a VBM
|2 Other
650 _ 7 |a VIM
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Essential Tremor: therapy
|2 MeSH
650 _ 2 |a Essential Tremor: diagnostic imaging
|2 MeSH
650 _ 2 |a Essential Tremor: pathology
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Ventral Thalamic Nuclei: diagnostic imaging
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging
|2 MeSH
650 _ 2 |a Cerebral Cortex: diagnostic imaging
|2 MeSH
650 _ 2 |a Cerebral Cortex: pathology
|2 MeSH
650 _ 2 |a Gray Matter: diagnostic imaging
|2 MeSH
650 _ 2 |a Gray Matter: pathology
|2 MeSH
650 _ 2 |a Neural Pathways: diagnostic imaging
|2 MeSH
650 _ 2 |a Neural Pathways: pathology
|2 MeSH
650 _ 2 |a Cerebellum: diagnostic imaging
|2 MeSH
650 _ 2 |a Cerebellum: pathology
|2 MeSH
650 _ 2 |a High-Intensity Focused Ultrasound Ablation: methods
|2 MeSH
650 _ 2 |a Thalamus: diagnostic imaging
|2 MeSH
650 _ 2 |a Thalamus: pathology
|2 MeSH
700 1 _ |a Upadhyay, Neeraj
|0 P:(DE-2719)2812558
|b 1
|u dzne
700 1 _ |a Purrer, Veronika
|0 P:(DE-2719)9000867
|b 2
|u dzne
700 1 _ |a Borger, Valeri
|b 3
700 1 _ |a Daamen, Marcel
|0 P:(DE-2719)2811028
|b 4
|u dzne
700 1 _ |a Schmitt, Angelika
|0 P:(DE-2719)2810830
|b 5
|u dzne
700 1 _ |a Schmeel, Carsten
|0 P:(DE-2719)9001551
|b 6
700 1 _ |a Radbruch, Alexander
|0 P:(DE-2719)9001861
|b 7
|u dzne
700 1 _ |a Wüllner, Ullrich
|0 P:(DE-2719)2000056
|b 8
|u dzne
700 1 _ |a Boecker, Henning
|0 P:(DE-2719)2810726
|b 9
|e Last author
|u dzne
773 _ _ |a 10.1016/j.parkreldis.2025.107318
|g Vol. 132, p. 107318 -
|0 PERI:(DE-600)2027635-7
|p 107318
|t Parkinsonism & related disorders
|v 132
|y 2025
|x 1353-8020
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/276825/files/DZNE-2025-00338.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/276825/files/DZNE-2025-00338.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:276825
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 1
|6 P:(DE-2719)2812558
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9000867
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 4
|6 P:(DE-2719)2811028
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 5
|6 P:(DE-2719)2810830
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)9001861
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2000056
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2810726
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-07
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-07
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b PARKINSONISM RELAT D : 2022
|d 2025-01-07
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-07
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2025-01-07
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-07
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-07
920 1 _ |0 I:(DE-2719)1011202
|k AG Boecker
|l Positron Emissions Tomography (PET)
|x 0
920 1 _ |0 I:(DE-2719)1011001
|k Clinical Research (Bonn)
|l Clinical Research Coordination
|x 1
920 1 _ |0 I:(DE-2719)5000075
|k AG Radbruch
|l Clinical Neuroimaging
|x 2
920 1 _ |0 I:(DE-2719)1011302
|k AG Wüllner
|l Biomarker Parkinson's Disease
|x 3
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1011202
980 _ _ |a I:(DE-2719)1011001
980 _ _ |a I:(DE-2719)5000075
980 _ _ |a I:(DE-2719)1011302
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21